Asset Details
Do you wish to reserve the book?
1106 nELISA high-throughput proteomics captures immune secretomes for high-resolution phenotypic screens
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
1106 nELISA high-throughput proteomics captures immune secretomes for high-resolution phenotypic screens
Do you wish to request the book?
1106 nELISA high-throughput proteomics captures immune secretomes for high-resolution phenotypic screens
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
1106 nELISA high-throughput proteomics captures immune secretomes for high-resolution phenotypic screens
2024
Overview
BackgroundImmune phenotypes can be extremely diverse and complex, posing both a challenge to understand them and an opportunity to target them with advanced immune engineering approaches. Unfortunately, proteomics tools that capture the breadth of possible immune responses lack the throughput and affordability to rapidly profile the large sample numbers generated to identify and characterize optimally engineered therapeutic candidates. To overcome this issue, we developed the nELISA: a high-throughput miniaturized ELISA capable of quantifying >275 cytokines, proteases, immune receptors, and growth factors, at 10x-reduced cost compared to previous tools. Here, we applied the nELISA to model systems as a proof-of-concept for use in immune engineering.MethodsWe ran the largest PBMC secretome screen to date, in which ~10,000 PBMC samples were profiled in 1 week, at a throughput of 1536 samples/day. Cells were treated with various inflammatory stimuli, and were further perturbed with a selected library of 80 recombinant protein perturbagens.ResultsThe broad nELISA content enabled us to capture disease phenotypes and donor variability, as well as distinguish between perturbations with similar effects on single markers but vastly different overall phenotypes. For example, IFN gamma was potently induced by >12 perturbagens with very different effects on other cytokines. Thus, IL-23 had almost no impact other than to induce IFN gamma; in contrast, IL-15 also induced IL-1 beta, TNF alpha, CXCL9, CXCL10, and CCL5, whereas IFN beta impacted the expression of >20 cytokines in addition to IFN gamma. Interestingly, we also identified cases perturbagens that could substitute for another, while avoiding deleterious effects. Thus, IL-1 Receptor antagonist shared all of the immunosuppressive effects of IFN beta, without inducing IFN gamma and CXCL10, supporting its use as a replacement for Type I interferons in certain indications such as multiple sclerosis.ConclusionsThese findings highlight the ability of the nELISA to capture a wide range of immune phenotypes at a throughput and cost amenable to immune engineering studies.
Publisher
BMJ Publishing Group LTD
Subject
